SGSilvana Galderisi

Silvana Galderisi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Silvana Galderisi has a total of 884 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Liability and Standard of Care in AI-Driven Psychiatric Practice: European Viewpoint

    by Luis Madeira, Cíntia Águas, Meryam Schouler-Ocak, Jerzy Samochowiec, Silvana Galderisi, Mariana Pinto da Costa

    AI is increasingly incorporated into psychiatric triage, risk prediction, passive monitoring, clinical documentation, and patient-facing conversational systems. These applications may improve access, continuity, efficiency, and pattern recognition, but they also redistribute epistemic authority and complicate responsibility when harm occurs. European regulation is developed in relation to market access, data governance, risk management, and product safety, yet remains fragmented regarding civil liability, organizational negligence, and the psychiatric standard of care. This Viewpoint examines how liability and standard of care should be understood when AI becomes part of psychiatric reasoning in Europe. It advances one central thesis: psychiatric AI requires justified integration supported by layered accountability within, but not determined by, European regulation. It presents a targeted doctrinal and normative synthesis of binding European Union instruments, regulatory guidance, selected national governance materials, and psychiatric, bioethical, legal, and digital mental health literature. It distinguishes binding law from guidance and policy, and separates ex ante regulation from ex post liability, and from professional standards of care. Four illustrative domains are analyzed: conversational or therapeutic chatbots, suicide prediction, digital phenotyping and passive monitoring, and large language model documentation. Psychiatric AI raises distinctive concerns because psychiatric judgment depends heavily on testimony, contextual meaning, therapeutic trust, risk interpretation, privacy, and liberty-sensitive decisions. Existing European instruments, including the AI Act, Medical Device Regulation, General Data Protection Regulation, revised Product Liability Directive, and European Health Data Space Regulation, establish governance duties, but do not provide a harmonized fault-based liability framework for AI-assisted health care. Regulatory compliance may inform later legal assessment, but it does not determine whether psychiatric care was reasonable. The proposed standard of justified integration requires knowledge of intended use and model limits, assessment of local and patient-level applicability, active clinical interpretation, disclosure when AI use is material to consent or trust, documentation in high-stakes decisions, and organizational audit. Accountability should be distributed across developers, deployers, and clinicians according to control and preventability. Mixed-fault scenarios are therefore likely to be common. The augmented-clinician model and layered accountability are offered as normative proposals rather than settled European legal standards. Clinicians should remain responsible for contextual, patient-centered judgment; developers for design, validation, documentation, and foreseeable misuse; and deployers for procurement, training, workflow integration, local validation, monitoring, and escalation. Future empirical research should evaluate effects on clinician reliance, documentation burden, patient outcomes, coercive interventions, therapeutic trust, and feasibility across differently resourced services.

  • Open Access

    Weight and metabolic changes in patients with schizophrenia treated with paliperidone palmitate 6-month formulation versus paliperidone palmitate 3-month formulation: a post-hoc analysis

    by Mark Guirguis, Robert Karl Knight, Panna Sanga, John Han, Silvana Galderisi

    Objective: To determine the effect that paliperidone palmitate 6-month long-acting injectable formulation (PP6M) had on metabolic parameters including body weight (BW), and blood lipid profiles, a post-hoc analysis was conducted to assess changes in BW from baseline to the end of study based on age, body mass index (BMI), and changes in blood lipid profiles during a 12-month, phase 3, double-blind (DB) clinical study. Long term effects of PP6M on BW and BMI were further explored during a 24-month extension study in which participants were treated exclusively with PP6M. Method: In the 12-month DB phase, participants were randomized to receive PP6M or paliperidone palmitate 3-month long-acting injectable formulation (PP3M). The mean change in BW and abnormal weight percent change from baseline were calculated at endpoint by age, gender, and BMI. Additionally, treatment-emergent shifts from baseline for the four key lipid parameters (fasting low density lipoprotein [LDL], fasting triglycerides [TG], fasting total cholesterol [TC], and fasting high density lipoprotein [HDL]) during DB were assessed. Following this study, participants were given the opportunity to transition to a 24-month extension study and be treated with PP6M. The mean change and percent change in BW, and the mean change in BMI from DB baseline to the end of the extension study (36 months total) were calculated. Results: Participants who were treated with PP6M showed numerically less weight gain, BMI, waist circumference, and more weight decrease compared to PP3M group during 12-month DB phase, though the proportion of participants reporting an abnormal change (≥7% change) in BW did not significantly differ between PP3M and PP6M. The weight differences were more pronounced in the younger age group (18-25 years) and those who were overweight (BMI: 25 to <30 kg/m2. Numerical differences in favor of PP6M were found in fasting blood lipids (HDL, LDL, TG, and TC). The changes in BW and BMI over time remained consistent throughout the 24-month extension, favoring PP6M in each instance. Conclusions: This post-hoc analysis demonstrated that PP6M was comparable to PP3M in terms of metabolic parameters; however, it may have a beneficial effect on weight gain, especially in young patients. Trial registration: Post-Hoc Analysis of Studies NCT03345342 and NCT04072575 (ClinicalTrials.gov). Significant outcomes The findings from this study have highlighted that participants who were treated with the 6-month long-acting injectable formulation of paliperidone exhibited less weight gain during treatment overall, and significantly less weight gain in adolescents and young adults. Importantly, this trend continued over the course of long-term treatment, regardless of age. Participants treated with the 6-month formulation also had fewer shifts in blood lipids outside of the normal range and had more favorable changes in body mass index and waist circumference. These results suggest that when considering metabolic dysregulation as a factor in choosing a long-acting injectable antipsychotic, the 6-month formulation is a viable alternative to the 3-month formulation, particularly in younger patients with schizophrenia. Limitations Because this is a post hoc analysis and the study was not powered to test weight and metabolic changes, most endpoints were summarized descriptively and the statistical test was limited to the main endpoint (abnormal percent weight gain and loss).

  • Open Access

    Human rights-based mental healthcare: new developments, introducing a themed series of papers

    by Helen Herrman, Paul S. Appelbaum, Silvana Galderisi, Norman Sartorius, John Allan, Martha Savage, Maria Rodrigues, Neeraj Gill, Guadalupe Morales Cano

    Summary: Mental healthcare respecting human rights is a worldwide need, yet research into practices that support such rights is limited. The United Nations Convention on the Rights of Persons with Disabilities, 2006 and the United Nations Resolution on mental health and psychosocial support, 2023 each heighten the urgency and the legal, as well as moral, social, political and other obligations to improve the quality of mental healthcare and respect human rights worldwide. It is useful to be specific about the actions to be taken, as done in recent programmes by the World Psychiatric Association and the World Health Organization. The work requires partnerships at all levels, from global to local, among healthcare professionals, people with lived experience and their families, communities and policy-makers. We present a themed series of papers developed in two parts: one related to principles of human rights-based mental healthcare; the other to assessment, policy and actions needed for tackling the implementation gap.

  • Open Access

    Resting-State Functional Connectivity And Cognitive Impairment After Covid-19 Infection: Evidence From A Large-Scale fMRI Study

    by A. Perrottelli, S. Galderisi, M. Amore, S. Barlati, G. Cascino, M. Cirillo, D. Corbo, G. Di Lorenzo, F. Di Salle, F. Esposito, et al.

    The development of cognitive impairment (CI) is a frequent and debilitating consequence of COVID-19 and can persist for more than 1 year after the acute infection stage. Previous neuroimaging studies in COVID-19 survivors with CI have revealed widespread alterations in functional connectivity (FC), particularly within fronto-parietal circuits and subcortical nuclei such as the hippocampus, basal ganglia, and thalamus. This study focuses on neural correlates of CI in subjects who recovered from COVID-19 and the relationship between FC patterns and discrete cognitive domains. Resting-state functional MRI data from 136 subjects were analyzed using a ROI-to-ROI approach across 246 brain regions derived from the Human Brainnetome Atlas. Group comparisons were performed based on the presence or absence of CI, and correlation analyses were conducted between FC and scores obtained from a comprehensive neuropsychological test battery. Whole-brain FC showed no difference between patients with and without CI. In the whole study sample, hypoconnectivity between two basal ganglia regions and two frontal motor regions was associated with impaired performance in the cognitive domain “Reasoning and Problem-Solving,” while hyperconnectivity between the prefrontal thalamus and the postcentral gyrus was associated with impaired performance in the same cognitive domain. Our findings indicate that FC alterations within the cortico-striatal and thalamo-cortical circuits may subtend deficits in higher-order executive functions in post-COVID-19 patients and highlight the importance of examining discrete cognitive domains in relation to brain connectivity.

  • Open Access

    Understanding the burden of cognitive impairment associated with schizophrenia: Results from the international LUCIA study

    by Christoph U. Correll, Silvana Galderisi, Maite Artés, Ana Fernández, Bregt Kappelhoff, Walter D. Lawhorn, Sébastien Tulliez, Satoru Ikezawa, Åsa Konradsson-Geuken, Morgane Sheykhi Hagaieg, et al.

    Background: Cognitive impairment associated with schizophrenia (CIAS) is a prevalent, meaningful feature of schizophrenia with limited real-world data on its recognition and care setting impact. The LUCIA initiative is an international multi-stakeholder study that explored awareness, assessment practices, and the burden of CIAS to inform future care pathways. Methods: A three phase, Delphi-informed design was applied, comprising expert interviews to frame the enquiry, qualitative interviews with health and social care professionals (HCPs; n = 74) and caregiver advocates (n = 11), two waves of a Delphi survey among HCPs (n=449 and 343, respectively) and one round among 61 patients and 112 caregivers across 15 countries (n = 964). Results: The results showed poor awareness of CIAS across stakeholders. Structured cognitive assessment was infrequent, and clinicians largely relied on the dementia oriented Mini-Mental State Examination (MMSE) rather than schizophrenia specific tools, citing time, training, and unclear actionability as key barriers. CIAS imposed broad humanistic, clinical, societal, and economic burden – poorer quality of life, social isolation, higher comorbidities, increased hospital days and health care costs, and heavy informal care. Consensus actions prioritized the development of brief, validated screening instruments, improved psychoeducation, and accelerated research into effective pharmacological and non pharmacological interventions. Conclusions: These results provide additional evidence for the under-recognition of CIAS worldwide, despite its substantial multidimensional societal burden. The use of dementia-oriented cognitive tests carries significant risks of misclassification and inappropriate management. Therefore, improving awareness, implementing assessment guidelines, and accelerating therapeutic innovation is critical to improve the quality of life of CIAS patients and the wider community.

  • Open Access

    Persistent negative symptoms in the EULAST cohort: impact on functional outcome

    by Luigi Giuliani, Pasquale Pezzella, Giulia M. Giordano, Andrea Perrottelli, Armida Mucci, Paola Bucci, Istvan Bitter, Celso Arango, Jurjen J. Luykx, Covadonga M. Díaz-Caneja, et al.

    Persistent negative symptoms (PNS), defined as negative symptoms of at least moderate severity that endure over time and are not attributable to other psychopathological dimensions such as depression or parkinsonism, have been associated with poor functional outcomes in schizophrenia, in both chronic stages and in the early phases of the disorder. This post-hoc analysis of a large cohort of schizophrenia spectrum disorder patients within their first 7 years of illness, enrolled in the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST), aimed to: 1) confirm prior findings about the prevalence and clinical impact of unconfounded persistent negative symptoms (PNS) on dropout rates and psychosocial functioning after 12 and 18 months of treatment; and 2) explore the prevalence of enduring negative symptoms (E-NS), defined as persistent negative symptoms either confounded or unconfounded by depression or parkinsonism, and their influence on functional outcome. At week 0, 60.6% of patients exhibited at least one negative symptom of moderate severity. Among them, 42.8% met criteria for unconfounded negative symptoms. After 1 year, the frequency of PNS and E-NS was 7.9% and 15%, respectively, with a prospective consistency around 32%. PNS subjects had similar levels of functioning at week 0 ( d = −0.179, p = 0.194), but worse functioning after 12 ( d = −0.697, p = 0.028) and 18 ( d = -0.676, p = 0.024) months of treatment, as compared to those with negative symptoms of similar severity at baseline that did not persist (non-persistent negative symptoms, N-PNS). No difference among groups was observed in drop-out rates. The comparison between the E-NS and N-PNS groups revealed the same functional outcome differences observed in the PNS versus N-PNS comparison. Our findings confirm that long-term persistence of negative symptoms, both primary and secondary, contributes to poor functional outcome. Future research should focus on identifying predictors of symptom persistence to guide the development of targeted interventions aimed at improving long-term functional outcomes in this patient population.


  • Open Access

    Rethinking Schizophrenia: Optimizing Care Pathways in Europe from the First Episode of Psychosis to Long-Term Care

    by Pavel Mohr, Geert Dom, Peter Falkai, Celso Arango, Istvan Bitter, Julian Beezhold, Patrice Boyer, Ana Catalan, Boris Chaumette, Sonia Dollfus, et al.

    Background: The European Brain Council project “Rethinking Schizophrenia” aims to examine the existing state of patient care pathways across Europe. The study objectives of Phase 2 were to evaluate the current models of schizophrenia care on mental health outcomes, access and satisfaction with care, and to identify the foundations of integrated care pathways for young people with first-episode psychosis. Methods: Using the care pathway, a questionnaire was developed and anonymously disseminated to mental health professionals in nine European countries (Belgium, Denmark, France, Germany, Hungary, Italy, Poland, Spain, and the United Kingdom). The survey included 45 questions and addressed the quality and continuity of care from the first onset of psychosis to long-term care, including assessment of the mental health care systems. Results: A total of 203 responses were obtained. The majority of mental health professionals were psychiatrists (75%), followed by psychologists (11%), nurses (7%), social workers (2%), and GPs and others (5%). The responses were analyzed qualitatively. The results revealed dissatisfaction with the current state of schizophrenia care systems and significant variability in quality of care. The factors that affect the care pathways most are assessment and early intervention services, continuity of care, availability of various types of services and treatments, collaborative decision-making, and utilization of new technologies. Conclusions: A comprehensive, integrated approach is essential to improve schizophrenia care across Europe. This strategy emphasizes early intervention, equitable access to treatments, coordinated care models, psychosocial support, and long-term recovery through a biopsychosocial framework and emerging technologies.

  • Open Access

    Early career psychiatrists’ ability to evaluate and manage negative symptoms of schizophrenia – Results from a European survey

    by Anna Julia Krupa, Marcin Siwek, Tomasz Gondek, Gaia Sampogna, Renato de Filippis, Aistė Lengvenytė, Beren Özel, Cristiana Tăpoi, Visnja Banjac Baljak, Stefan Jerotic, et al.

    Background: Negative symptoms (NS) represent an important unmet need in schizophrenia (SZ) assessment and management. Despite NS are strongly associated with poorer functioning and quality of life, they are frequently underrecognized, inconsistently evaluated, and show limited response to current treatments. Although specific assessment tools and European Psychiatric Association (EPA) guidance on NS have been developed, their impact on routine clinical practice appears limited. This study aimed to investigate the competence and confidence of European Early Career Psychiatrists (ECPs) in NS evaluation and management. Methods: The CARE project was a cross-sectional online survey directed towards ECPs from European countries. Results: 828 ECPs’ responses were collected from 19 countries. The majority of ECPs were trainees (65.8%), reported theoretical training in negative symptoms (NS) and placements in schizophrenia-specialized settings (67.9% and 70.3%), while about half reported extracurricular NS training (51.1%) and involvement in clinical research (46.1%). Only 11% correctly identified NS domains, despite 65.7% felt well-trained in NS assessment tools. Just 15.9% correctly answered questions based on the EPA guidance papers. 46.7% and 25.9% ECPs reported feeling competent in NS evaluation and management, respectively. Gender (men) specialist status, research involvement, theoretical NS training, and placements in specialized SZ services predicted perceived competence. However, in-depth NS knowledge was predicted only by specialist status, engagement in clinical research, and extracurricular NS training. Conclusions: Despite reported exposure to NS training, ECPs demonstrated limited knowledge of NS. Actions need to be taken to ensure that ECPs receive the highest standard of training in NS.

  • Open Access

    Policy paper of the Committee on Ethics and Task Force on Migration and Mental Health: Migration and mental health of migrants, refugees, asylum seekers – Ethical dilemmas and concerns

    by Meryam Schouler-Ocak, Sofie Bäärnhielm, Ilaria Tarricone, Kristina Adorjan, Jerzy Samochowiec, Egor Chumakov, Apostolos Veizis, Ahmet Tamer Aker, Silvana Galderisi, Sam Tyano, et al.

    Background: International migration is a complex phenomenon of global and historical relevance. It includes voluntary, forced, and workforce migration, shaped by diverse determinants. Push factors comprise war, persecution, and political instability, while pull factors include stability, economic opportunities, education, and favorable living conditions. Forced migration is frequently associated with displacement and a disproportionate burden of mental health disorders, which are urgent yet difficult to address due to structural, cultural, and legal barriers. Methods: Evidence demonstrates that restricted health care access exacerbates psychiatric disorders, while treatment delays contribute to poorer outcomes. Barriers include administrative limitations, linguistic and cultural differences, stigma, and resource shortages. This policy paper was developed by the Committee on Ethics and the Task Force on Migration and Mental Health of the European Psychiatric Association (EPA). Relevant literature was reviewed and combined with the professional expertise of committee members. The draft was subsequently evaluated by the Publication Committee and the EPA Board, and revised accordingly. Results: Ethical principles in refugee care are insufficiently implemented in many European countries. Core principles of medical ethics – beneficence, respect for autonomy, non-maleficence, and justice – as well as the obligation to advance psychiatric standards and apply psychiatric expertise for societal benefit, are inconsistently upheld. Conclusions: The primary duty of physicians is to promote health and well-being through competent, timely, and compassionate care. The EPA therefore advocates coordinated strategies to mitigate the mental health consequences of war, displacement, and trauma, and to secure equitable access to psychiatric services for migrants and refugees.